A. Guyot-goubin, J. Donadieu, M. Barkaoui, S. Bellec, C. Thomas et al., Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, Pediatr Blood Cancer. juill, vol.51, issue.1, pp.71-76, 2000.
URL : https://hal.archives-ouvertes.fr/inserm-00255977

H. Stålemark, E. Laurencikas, J. Karis, D. Gavhed, B. Fadeel et al., Incidence of Langerhans cell histiocytosis in children: a population-based study, Pediatr Blood Cancer. juill, vol.51, issue.1, pp.76-81, 2008.

K. Chikwava and R. Jaffe, Langerin (CD207) staining in normal pediatric tissues, reactive lymph nodes, and childhood histiocytic disorders, Pediatr Dev Pathol Off J Soc Pediatr Pathol Paediatr Pathol Soc. déc, vol.7, issue.6, pp.607-621, 2004.

J. Picarsic and R. Jaffe, Nosology and Pathology of Langerhans Cell Histiocytosis, Hematol Oncol Clin North Am, vol.29, issue.5, pp.799-823, 2015.

S. K. Lau, P. G. Chu, and L. M. Weiss, Immunohistochemical expression of Langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytic disorders, Am J Surg Pathol. avr, vol.32, issue.4, pp.615-624, 2008.

J. Valladeau, O. Ravel, C. Dezutter-dambuyant, K. Moore, M. Kleijmeer et al., Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules, Immunity. janv, vol.12, issue.1, pp.71-81, 2000.

J. Emile, O. Abla, S. Fraitag, A. Horne, J. Haroche et al., Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages, Blood, vol.127, issue.22, pp.2672-2681, 2016.

R. Haupt, M. Minkov, I. Astigarraga, E. Schäfer, V. Nanduri et al., Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years: Guidelines for Langerhans Cell Histiocytosis, Pediatr Blood Cancer. févr, vol.60, issue.2, pp.175-84, 2013.

R. Haupt, V. Nanduri, M. G. Calevo, C. Bernstrand, J. L. Braier et al., Permanent consequences in Langerhans cell histiocytosis patients: A pilot study from the Histiocyte Society?Late Effects Study Group, Pediatr Blood Cancer. mai, vol.42, issue.5, pp.438-482, 2004.

J. Donadieu, F. Chalard, and E. Jeziorski, Medical management of langerhans cell histiocytosis from diagnosis to treatment, Expert Opin Pharmacother. juin, vol.13, issue.9, pp.1309-1331, 2012.

M. A. Barthez, E. Araujo, and J. Donadieu, Langerhans cell histiocytosis and the central nervous system in childhood: evolution and prognostic factors. Results of a collaborative study, J Child Neurol. mars, vol.15, issue.3, pp.150-156, 2000.

N. Grois, B. Fahrner, R. J. Arceci, J. Henter, K. Mcclain et al., Central nervous system disease in Langerhans cell histiocytosis, J Pediatr. juin, vol.156, issue.6, p.1, 2010.

L. Guennec, L. Martin-duverneuil, N. Mokhtari, K. Santiago-ribeiro, M. Bayen et al., Neurohistiocytose langerhansienne. Presse Médicale, janv, vol.46, issue.1, pp.79-84, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01395227

J. Donadieu and S. Héritier, Histiocytose langerhansienne de l'enfant. Presse Médicale, vol.46, pp.85-95, 2017.

M. Steiner, S. Matthes-martin, A. Attarbaschi, M. Minkov, N. Grois et al., Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning, Bone Marrow Transplant, vol.36, issue.3, pp.215-225, 2005.

J. Donadieu, F. Bernard, M. Van-noesel, M. Barkaoui, O. Bardet et al., Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study, Blood. 17 sept, vol.126, issue.12, pp.1415-1438, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01231424

S. Weitzman, J. Braier, J. Donadieu, R. M. Egeler, N. Grois et al., 2?-chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the histiocyte society, Pediatr Blood Cancer. 15 déc, vol.53, issue.7, pp.1271-1277, 2009.

G. Badalian-very, J. Vergilio, B. A. Degar, L. E. Macconaill, B. Brandner et al., Recurrent BRAF mutations in Langerhans cell histiocytosis, Blood. 16 sept, vol.116, issue.11, pp.1919-1942, 2010.

J. Haroche, C. F. Arnaud, L. Von-deimling, A. Helias-rodzewicz, Z. Hervier et al., High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other nonLangerhans cell histiocytoses, Blood. 27 sept, vol.120, issue.13, pp.2700-2703, 2012.

S. Héritier, J. Emile, M. Barkaoui, C. Thomas, S. Fraitag et al., BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy, J Clin Oncol. sept, vol.34, issue.25, pp.3023-3053, 2016.

J. Haroche, F. Cohen-aubart, E. Arnaud, L. Maksud, P. Charlotte et al., Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation, Blood, vol.121, issue.9, pp.1495-1500, 2013.

S. Héritier, M. Jehanne, G. Leverger, J. Emile, J. Alvarez et al., Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis, JAMA Oncol. 1 sept, vol.1, issue.6, p.836, 2015.

A. Daud and K. Tsai, Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma, The Oncologist. juill, vol.22, issue.7, pp.823-856, 2017.

L. Boussemart, E. Routier, C. Mateus, K. Opletalova, G. Sebille et al., Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients, Ann Oncol. juin, vol.24, issue.6, pp.1691-1698, 2013.

R. Dummer, S. M. Goldinger, C. P. Turtschi, N. B. Eggmann, O. Michielin et al., Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study, Eur J Cancer Oxf Engl, vol.50, issue.3, pp.611-632, 1990.

B. Gençler and M. Gönül, Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature, Dermatol Res Pract, vol.2016, pp.1-6, 2016.

J. Larkin, D. Vecchio, M. Ascierto, P. A. Krajsova, I. Schachter et al., Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study, Lancet Oncol. avr, vol.15, issue.4, pp.436-480, 2014.

E. Y. Chu, K. A. Wanat, C. J. Miller, R. K. Amaravadi, L. A. Fecher et al., Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study, J Am Acad Dermatol. déc, vol.67, issue.6, pp.1265-72, 2012.

G. W. Robinson, B. A. Orr, and A. Gajjar, Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy, BMC Cancer. 12 avr, vol.14, p.258, 2014.

F. Bautista, A. Paci, V. Minard-colin, C. Dufour, J. Grill et al., Vemurafenib in pediatric patients with BRAFV 600E mutated high-grade gliomas: Vemurafenib in Pediatric High-Grade Gliomas, Pediatr Blood Cancer. juin, vol.61, issue.6, pp.1101-1104, 2014.

N. Finelt, R. R. Lulla, H. Melin-aldana, J. S. Ruth, F. Y. Lin et al., Bumps in the Road: Panniculitis in Children and Adolescents Treated with Vemurafenib, Pediatr Dermatol. mai, vol.34, issue.3, pp.337-378, 2017.

F. Del-bufalo, A. Carai, L. Figà-talamanca, B. Pettorini, C. Mallucci et al., Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent, J Transl Med, vol.12, 2017.

S. A. Upadhyaya, G. W. Robinson, J. H. Harreld, P. D. Klimo, M. E. Hoehn et al., Marked functional recovery and imaging response of refractory optic pathway glioma to BRAFV600E inhibitor therapy: a report of two cases, Childs Nerv Syst. avr, vol.34, issue.4, pp.605-615, 2018.

J. C. Chisholm, J. Suvada, I. J. Dunkel, M. Casanova, W. Zhang et al., BRIM-P: A phase I, openlabel, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma. Pediatr Blood Cancer, 2018.

D. Rizzo, A. Ruggiero, M. Amato, P. Maurizi, R. Riccardi et al., pediatric glioma: new therapeutic strategies, new toxicities, vol.12, pp.1397-405, 2016.

Z. Váradi, R. Bánusz, J. Csomor, K. Kállay, E. Varga et al., Effective BRAF inhibitor vemurafenib therapy in a 2-year-old patient with sequentially diagnosed Langerhans cell histiocytosis and Erdheim–Chester disease, OncoTargets Ther. janv, vol.10, pp.521-527, 2017.

M. Skrypek, N. Foreman, D. Guillaume, and C. Moertel, Pilomyxoid astrocytoma treated successfully with vemurafenib: Pilomyxoid Astrocytoma and Vemurafenib. Pediatr Blood Cancer, vol.61, pp.2099-100, 2014.

G. A. Mcarthur, P. B. Chapman, C. Robert, J. Larkin, J. B. Haanen et al., Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study, Lancet Oncol. mars, vol.15, issue.3, pp.323-355, 2014.

E. S. West, V. L. Williams, and J. G. Morelli, Vemurafenib-Induced Neutrophilic Panniculitis in a Child with a Brainstem Glioma, Pediatr Dermatol, vol.32, issue.1, pp.153-154, 2015.

M. E. Lacouture, M. Duvic, A. Hauschild, V. G. Prieto, C. Robert et al., Analysis of dermatologic events in vemurafenib-treated patients with melanoma, The Oncologist, vol.18, issue.3, pp.314-336, 2013.

J. P. Arnault, C. Mateus, B. Escudier, G. Tomasic, J. Wechsler et al., Skin Tumors Induced by Sorafenib; Paradoxic RAS-RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1, Clin Cancer Res. 1 janv, vol.18, issue.1, pp.263-72, 2012.

J. D. Rinderknecht, S. M. Goldinger, S. Rozati, J. Kamarashev, K. Kerl et al., RASopathic Skin Eruptions during Vemurafenib Therapy. Smalley K, éditeur, PLoS ONE. 14 mars, vol.8, issue.3, p.58721, 2013.

R. Sinha, K. Lecamwasam, K. Purshouse, J. Reed, M. R. Middleton et al., Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma, Br J Dermatol. avr, vol.170, issue.4, pp.997-1006, 2014.

M. Munch, L. Peuvrel, A. Brocard, S. Jean, M. Khammari et al., Early-Onset Vemurafenib-Induced DRESS Syndrome, Dermatology, vol.232, issue.1, pp.126-134, 2016.

G. Jeudy, S. Dalac-rat, B. Bonniaud, A. Hervieu, T. Petrella et al., Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis, Br J Dermatol, vol.172, issue.5, pp.1454-1459, 2015.

M. Wantz, I. Spanoudi-kitrimi, A. Lasek, D. Lebas, J. Quinchon et al.,

, Ann Dermatol Venereol. mars, vol.141, issue.3, pp.215-223, 2014.

C. Brugière, A. Stefan, C. Morice, E. Cornet, A. Moreau et al., Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease, Br J Dermatol. déc, vol.171, issue.6, pp.1529-1561, 2014.

R. Dummer, J. Rinderknecht, and S. M. Goldinger, Ultraviolet A and Photosensitivity during Vemurafenib Therapy, N Engl J Med. 2 févr, vol.366, issue.5, pp.480-481, 2012.

R. Gabeff, H. Dutartre, A. Khammari, A. Boisrobert, J. Nguyen et al., Phototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressive, Eur J Dermatol EJD, vol.25, issue.5, pp.452-458, 2015.

S. Klaeger, B. Gohlke, J. Perrin, V. Gupta, S. Heinzlmeir et al., Chemical Proteomics Reveals Ferrochelatase as a Common Off-target of Kinase Inhibitors, ACS Chem Biol. 20 mai, vol.11, issue.5, pp.1245-54, 2016.

T. Cestari and K. Buster, Photoprotection in specific populations: Children and people of color, J Am Acad Dermatol. mars, vol.76, issue.3, pp.110-131, 2017.

. Vázquez-osorio-i, M. D. Sánchez-aguilar, S. García-rodiño, J. M. Suárez-peñaranda, and C. Aliste, Vázquez-veiga H. Vemurafenib-induced Neutrophilic Panniculitis: A New Case and Review of the Literature, Am J Dermatopathol, vol.38, issue.1, 2018.

R. Mössner, L. Zimmer, C. Berking, C. Hoeller, C. Loquai et al., Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature, J Eur Acad Dermatol Venereol. sept, vol.29, issue.9, pp.1797-806, 2015.

M. Negulescu, F. Deilhes, V. Sibaud, E. Tournier, L. Lamant et al., Panniculitis Associated with MEK Inhibitor Therapy: An Uncommon Adverse Effect, Case Rep Dermatol. 21 mars, vol.9, issue.1, pp.80-85, 2017.

A. P. Villani, D. Zaharia, S. Dalle, L. Depaepe, B. Balme et al., Vemurafenib-induced panniculitis, Eur J Dermatol EJD. 1 avr, vol.23, issue.2, pp.258-60, 2013.

G. Hatzivassiliou, K. Song, Y. I. Brandhuber, B. J. Anderson, D. J. Alvarado et al., RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth, Nature. 18 mars, vol.464, issue.7287, pp.431-436, 2010.

F. Su, A. Viros, C. Milagre, K. Trunzer, G. Bollag et al., RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors, N Engl J Med, vol.366, issue.3, pp.207-222, 2012.

P. A. Oberholzer, D. Kee, P. Dziunycz, A. Sucker, N. Kamsukom et al., RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors, J Clin Oncol. 20 janv, vol.30, issue.3, pp.316-337, 2012.

, Classification HCL selon la classification de l'Histiocyte Society Cette classification se fait en fonction du nombre, du type d'organe ou de système atteint et par la présence d, ANNEXES Annexe, vol.1

. Les, SS : un seul organe atteint sauf les poumons ou un RO MS RO-: plusieurs organes atteints sauf les poumons ou RO Lung+ : atteinte des poumons isolée ou avec d'autres organes sauf RO

R. Ms, atteinte d'au moins un RO avec possibilité d'une atteinte des autres organes sauf les poumons ND : déficit(s) neurologique(s) évolutif(s) irréversible(s) et caractéristiques IRM spécifiques

R. Haupt, M. Minkov, I. Astigarraga, E. Schäfer, V. Nanduri et al., Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years: Guidelines for Langerhans Cell Histiocytosis. Pediatr Blood Cancer. févr burns, never tans (pale white

, Type 2 usually burns, tans minimally (white; fair; blond or red hair; blue, green

, ? Type 3 sometimes mild burn, tans uniformly

, Type 6 never burns, never tans (deeply pigmented dark brown to darkest brown)

T. B. Fitzpatrick, The validity and practicality of sun-reactive skin types i through vi, Archives of Dermatology, vol.124, issue.6, pp.869-871, 1988.